期刊文献+

重组人血管内皮抑制素联合腔内化疗治疗恶性胸腔积液疗效观察 被引量:1

Clinical observation of the efficacy of intracavitary injection of endostar combined with chemotherapy on ma-lignant pleural effusion
原文传递
导出
摘要 目的:观察重组人血管内皮抑制素(恩度)联合腔内化疗治疗恶性胸腔积液的疗效和安全性。方法46例恶性胸腔积液患者非随机分为腔内恩度联合化疗组(治疗组)和腔内化疗组(对照组)。治疗前均先排尽胸水,治疗组在胸腔内注入顺铂(DDP)60 mg和恩度45 mg。对照组除不加入恩度外,其余同治疗组,每周2次,共2~4次,观察两组疗效和安全性。结果治疗组有效率为58.3%,对照组有效率为31.8%,两组差异有统计学意义(χ^2=4.547,P<0.05);治疗组生活质量改善率为75.0%,对照组为59.1%,两组差异有统计学意义(χ^2=5.371,P<0.05);治疗组毒性反应与对照组相近,未明显增加。结论腔内恩度联合化疗治疗恶性胸腔积液安全有效。 Objective To study the efficacy and safety of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion.Methods 46 cases with malignant pleural effusion were divided into groups of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion (treatment group)and groups of intracavitary chemotherpy(control group)randomly,pleural effusion of the patients from the two groups were injected cisplatin(DDP)60mg into the thorax and 45mg of endostar,The same therapy applied to the control group except adding endostar,twice a week,in 2 -4 rounds,the efficacy and safety of the two groups were studied.Results The effective rate of the treatment groups was 58.3%,which was higher than 31.8%of the control group (χ^2 =4.547,P〈0.05).The improvement rate of quality of life was 75.0% in the treatment group,which was higher than 59.1% in the control group (χ^2 =5.371,P〈0.05).The toxicities of the treatment group were not increased significantly.Conclusion The therapy of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion is effective and secure.
出处 《中国基层医药》 CAS 2015年第8期1212-1214,共3页 Chinese Journal of Primary Medicine and Pharmacy
关键词 重组人血管内皮抑制素 恶性胸腔积液 腔内化疗 Endostar Malignant pLeuraL effusion Intracavitary chemotherapy
  • 相关文献

参考文献15

  • 1孙燕,石远凯.实用肿瘤内科学[M].北京:人民卫生出版社,2009:80.
  • 2陈群,石琴,谢强,肖松,李育宏,林江平,王成辉,王琳.重组人血管内皮抑制素联合化疗治疗恶性浆膜腔积液的临床观察[J].临床肿瘤学杂志,2008,13(10):938-941. 被引量:27
  • 3Haas AR, Sterman DH, Musani AL Malignant pleural effusions: Managementoptions with consideration of coding, billing, and a deci sionapproach [ J ]. Chest,2007,132 (3) : 1036-1041.
  • 4罗东,尹杰,柯有力.艾迪注射液联合卡铂胸腔灌注治疗恶性胸水的临床疗效[J].中国实用医刊,2014,41(16):17-18. 被引量:4
  • 5李磊,陈涛.恶性胸腔积液的治疗现状[J].华中医学杂志,2009,33(4):223-224. 被引量:12
  • 6Tamsma JT, Keizer H J, Meinders AE. Pathogenesis of maLignant ascites : starling's Law of capiLLary hemodynamics revisited [ J ]. Ann OncoL,2001,12 (10) : 1353-1357.
  • 7Fernanodo NT, Koch M, Rothrock C, at al. Tumor escape from en- dogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors [ J ]. Clin cancer Res,2008,14 (5) : 1529-1539.
  • 8Zhang X, Xu J, Lawler J, et al. Adeno-associated Virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin [ J ]. Clin Cancer Res,2007,13 ( 13 ) :3968-3976.
  • 9Xu F, Ma Q, Sha H. Optimizing drag delivery for enhancing thera- peutic efficacy of recombinant human endostatin in cancer treat- memt[ J ]. Crit Bey Ther Drug Cartier Syst, 2007,24 ( 5 ) : 445- 492.
  • 10Verheulh M, Hoekmann K, Jorua AS, et al. Targeting Vacsular en- dothelial growth factor bLockade : ascitest and pLeuraL effusion fo- mraiton [ J]. Oncologist ,2000,5 ( Suppll ) :45-50.

二级参考文献71

共引文献96

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部